ACH
MLYS icon

ArrowMark Colorado Holdings’s Mineralys Therapeutics MLYS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-62,500
Closed -$979K – 311
2023
Q1 		$979K Buy
+62,500
New +$1.05M 0.01% 253

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ArrowMark Colorado Holdings's MLYS Position: Q2 2023 in Review

ArrowMark Colorado Holdings sold out of Mineralys Therapeutics (MLYS) in Q2 2023, closing a stake of 62,500 shares — an estimated $979K sold.

ArrowMark Colorado Holdings first reported a position in MLYS in Q1 2023 and held it in 1 quarter. The position peaked at $979K in Q1 2023. 68 funds tracked by Wall St. Rank hold MLYS as of Q2 2023.

  • ArrowMark Colorado Holdings reported no remaining Mineralys Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 62,500 Mineralys Therapeutics shares in Q2 2023, an estimated $979K.
  • ArrowMark Colorado Holdings first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Mineralys Therapeutics position peaked at $979K in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2023.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.